VIEWS40LIKES2
Rena Conti@contirena1
@RuxandraTeslo 100%
2hViews 40Likes 2
Original post unavailable.
Sentiment
Many users agree FDA manufacturing rules threaten cell therapy firms and patient access, with positives excited about in vivo CAR-T alternatives while negatives note the FDA blocks AI advances in biology.
Pos
66.7%
Neg
33.3%
3 comments with sentiment.
Cluster Engagement
Posts from X
Most Activity
Most Activity
REPLIES1
Jake Becraft@DrSynbio
@RuxandraTeslo To be fair, we also need to think about better ways to deliver these medicines. Autologous Cell therapy is a fantastic proof of concept, but if we can’t figure out how to make these medicines more broadly scalable without multi billion dollar infrastructure buildout, we’ve failed
2hViews 18
Michelangelo G.@oxMichelangelo
@RuxandraTeslo yeah all these people saying that AI will solve biology have forgotten about the FDA
2hViews 24
Ruxandra Teslo 🧬@RuxandraTeslo
@DrSynbio I agree. In vivo CAR Ts for example are super exciting for this reason.
However, we can't wait for a new tech to always save us. We should be efficient abt how we regulate these things from the get-go.
2hViews 6